Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Long-term follow-up

Main Article Content

Alexander J Stratigos
Aleksandar Sekulic
Ketty Peris
Oliver Bechter
Sorilla Prey
Martin Kaatz
Karl D Lewis
Nicole Basset-Seguin
Anne Lynn S Chang
Stéphane Dalle
Almudena Fernandez Orland
Lisa Licitra
Caroline Robert
Claas Ulrich
Axel Hauschild
Michael R Migden
Reinhard Dummer
Suk-Young Yoo
Ebony Coates
Emmanuel Okoye
Ioannis Bassukas
Carmen Loquai
Vincenzo De Giorgi
Zeynep Eroglu
Ralf Gutzmer
Jens Ulrich
Susana Puig
Frank Seebach
Israel Lowy
Matthew G Fury




1. Puig S et al. Clin Transl Oncol. 2015;17:497–503.

2. Monroe M et al. Otolaryngol Clin North Am. 2021;54:271–280.

3. Sekulic A et al. N Engl J Med. 2012;366:2171–2179.

4. Migden MR et al. Lancet Oncol. 2015;16:716–728.

5. Basset-Seguin N et al. Lancet Oncol. 2015;16:729–736.

6. Burova E et al. Mol Cancer Ther. 2017;16:861–870.

7. Regeneron Pharmaceuticals, Inc. Available at: [Accessed January 22, 2022].

8. Regeneron Pharmaceuticals, Inc. Available at: [Accessed January 22, 2022].

9. Health Canada. Available at: [Accessed January 22, 2022].

10. Ministry of Health Israel. Available at:!/medDetails/164%2099%2036023%2000. [Accessed January 22, 2022].

11. Brazilian Health Authority - ANVISA. Available at: [Accessed January 22, 2022].

12. Stratigos AJ et al. Lancet Oncol. 2021;22:848–857.

13. Lewis K et al. J Immunother Cancer. 2020;8:Abstract 428.

Most read articles by the same author(s)

1 2 3 > >>